Shaobo Chen

Shaobo Chen

Auto-generated profile, based on publicly available information

Shaobo Chen

Department of Prevention and Therapy of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of PAP

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Placenta
Verified
Journal Article
Closed access
YLYaguang Li
Yaguang Li
NYNing Yang
Ning Yang
BWBinsu Wang
Binsu Wang
XNXiulong Niu
Xiulong Niu
WCWei Cai
Wei Cai
SCShaobo Chen
Shaobo Chen

20 July 2020 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
XWXiujuan Wang
Xiujuan Wang
GLGuoqing Liang
Guoqing Liang
QGQing Guo
Qing Guo
WCWei Cai
Wei Cai
XZXin Zhang
Xin Zhang
SCShaobo Chen
Shaobo Chen

30 January 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
XNXiu-Long Niu
Xiu-Long Niu
XWXiao-Jing Wang
Xiao-Jing Wang
XZXin Zhang
Xin Zhang
WPWei Pang
Wei Pang
QGQiong Guo
Qiong Guo
RSRui Shi
Rui Shi
Background: Essential hypertension (EH) in young and middle-aged adults is a major risk factor for cardiovascular morbidity, yet the detailed molecular mechanisms underlying this condition have not been fully understood. MicroRNAs (miRNAs) have emerged as critical regulators of gene expression and have been increasingly associated with hypertension pathogenesis. Methods: Initially, high-throughput sequencing was employed to identify miRNAs with differential expression profiles in plasma collected from six EH patients compared with six matched healthy individuals. These candidate miRNAs were then confirmed through quantitative real-time PCR (qRT-PCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the potential biological roles of these miRNAs. Mendelian randomization (MR) was subsequently applied to investigate causal associations between EH and proteins targeted by the identified miRNAs. Results: Differential expression analysis revealed 14 upregulated miRNAs and 1 downregulated miRNA in the EH group. Following this, miRNAs were enriched through MiEAA, resulting in the selection of one downregulated miRNA and four upregulated miRNAs, which were subsequently validated by qRT-PCR. KEGG pathway analysis showed that genes regulated by upregulated miRNAs were significantly enriched in pathways related to hypoxia (HIF-1 signaling pathway), inflammation (MAPK and JAK-STAT signaling pathways), vascular remodeling (Focal adhesion and TGF-beta signaling pathways), and apoptosis (p53 signaling pathway). MR analysis identified GPCPD1, regulated by hsa-miR-10b-5p, as a significant risk factor for EH (OR = 1.04, 95% CI: 1.00–1.09, p = 2.32 × 10 −3 ). Moreover, proteins regulated by upregulated miRNAs, such as CDKN1B, PDGFRA, and THBS2, were found to be protective factors against EH. Conclusion: GPCPD1, regulated by hsa-miR-10b-5p, is a potential risk factor for EH, while CDKN1B, PDGFRA, and THBS2, regulated by upregulated miRNAs, may act as protective factors. These findings suggest new biomarkers and therapeutic targets for hypertension.